CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 157 enrolled
Drug / intervention
Wintergreen Throat Spray and Aspirin Tablet +3 moredrug
Likely dose
Wintergreen Throat Spray and Aspirin Tablet 325mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06106880
NCT06106880Phase 1Completed

Alleviation of Upper Respiratory Inflammation and Associated Common Cold Symptoms

Applied Biological Laboratories Inc·interventional·Posted Oct 30, 2023·Updated Jan 16, 2024

In Brief

A Phase 1 clinical trial evaluating Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, and 2 other interventions for Common Cold and 11 related conditions. Completed, enrolled 157 participants across 6 sites.

Detailed Summary

Upper respiratory infections (URIs) have long posed a significant burden to the US healthcare system. Well before the coronavirus disease of 2019 (COVID-19) pandemic they have been among the most common acute outpatient illnesses, causing 75-100 million physician visits each year on average, and costing the health care system billions of dollars annually. This double-blind randomized placebo-controlled study tested the efficacy of two anti-inflammatory throat sprays against placebo and against a throat spray taken in conjunction with 325mg of aspirin, a well-known systemically administered cyclooxygenase (COX) inhibitor. Participants having common cold symptoms lasting less than two days were enrolled and given treatment to administer at home. Various common cold symptoms were assessed and measured via clinically validated self-assessment scales. Participants were screened for influenza and COVID-19 before enrollment and were excluded if found positive.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsEconometrica, Inc.

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedOct 30, 2023
Enrollment StartMay 25, 2022
Primary CompletionApr 8, 2023
Study CompletionJun 16, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 2.7 years ago

Interventions

Wintergreen Throat Spray and Aspirin Tabletdrug

The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin. Aspirin in a 325mg tablet

Aspirin Throat Spray and Placebo Tabletdrug

The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin. Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients.

Wintergreen Throat Spray and Placebo Tabletdietary

The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin. The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients.

Placebo Throat Spray and Placebo Tabletother

The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener. The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients.